Oncolytic Vaccinia Virus in Lung Cancer Vaccines

Therapeutic Cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising Cancer treatment option for effective Cancer Immunotherapy and thus can also be utilized in Cancer vaccines. Non-small cell lung Cancer (NSCLC) is likely to respond to immunotherapy, such as Immune Checkpoint inhibitors or Cancer vaccines, since it has a high tumor mutational burden. In this review, we will summarize recent applications of VV in lung Cancer treatment and discuss the potential and direction of VV-based therapeutic vaccines.

cancer vaccine; immunotherapy; non-small cell lung cancer; oncolytic virus; personalized vaccination; vaccinia virus.